303 results about "Hepatitis virus c" patented technology

Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1:

wherein Z′, L′, M′, R₁, X and D are defined herein.

Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.

The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

Compounds having the formula I wherein A, m and R¹ are herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process

Disclosed is a process for preparing a macrocyclic compound of the formula (I):

which is carried out using an intermediate of the formula (II):

wherein W, R¹ through R⁴, D, A and R¹² are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Compounds are disclosed having the general formula:

wherein R₁, R₂, R₃, R₄, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Compounds of formula I:

wherein R¹ is hydroxy or NHSO₂R^1A wherein R^1A is (C_1-8)alkyl, (C_3-7)cycloalkyl or {(C_1-6)alkyl-(C_3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C_1-6)alkyl, amido, amino or phenyl, or R^1A is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C_1-6)alkyl, O(C_1-6)alkyl, amido, amino or phenyl; R² is (C_5-6)cycloalkyl and R³ is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:

useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.

The present invention relates to lactams of Formula (I):

or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Hepatitis C virus inhibitors are having the general formula:

• • wherein A, R₂, R₃, R′, B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

The invention relates to a nucleoside phosphamide prodrug as well as a preparation method and application of the nucleoside phosphamide prodrug. The nucleoside phosphamide prodrug is selected from any one of a compound I and a compound II, wherein in the formulas of the compound I and the compound II, X is selected from any one of F, Cl, Br and I. Compared with GS7977andGS7851, The compound I or II disclosed by the invention has more excellent resistance to hepatitis C virus, wherein the formulas I and II are respectively as shown in specifications.

The invention provides HCV fusion proteins that include a mutated NS3 protease domain, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4⁺ and CD8⁺ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.

The invention relates to a diagnostic reagent kit for testing the hepatitis c virus (HCV) and the preparation and test method, which is to add the HCV recombinant antigen used for peridium into the buffer solution, blend it, move into the luminous microplate, make incubation for 18 hours under 4DEG.C, wash the luminous microplate, add into the confining liquid, leave the liquid after incubation and fully dry the luminous microplate to complete the preparation of the pre-peridium luminous microplate; combine the anti-human IgG used for marking and the horse radish peroxidase by improving the sodium periodate to complete the preparation of the enzyme marker; prepare the chemical luminous substrate solution A with luminal, Tween20 and luminous intensifier and prepare the chemical luminous substrate solution B with the hydrogen peroxide. The reagent kit also comprises the sample diluent and concentrated scrub solution. The negative corresponds to the normal human serum while the positive corresponds to the people with serum of pooled serum with HCV antibody. The reagent kit provided in the invention has much higher detection sensitivity than the ELISA, which is safe and reliable, easy to operate with low cost, and without any expensive full-automatic chemical luminous measuring apparatus required.